The start-up of production lines is underway in many of the departments at the manufacturing plant and the majority of the plant's production lines are already up and running or at the start-up phase.
The preparations for the start-up of the manufacturing plant took just over three weeks. The interruption in production was shorter than initially estimated.
"The first production batches have been completed. Warehousing functions have also been able to unload the large deliveries of materials that have arrived at the plant," explains Iikka Keskinen, Director, Pharmaceutical Production at Orion.
Orion has also started manufacturing some of its more popular products at its Espoo plant to ensure good availability of all products.
Orion Corporation
Contact person:
Iikka Keskinen, Director, Pharmaceutical Production, Orion Corporation, tel. +358 50 966 2720
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2010 amounted to EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.